1. recent news of the anticipated April 2012 launch of Exparel. 2. Phase III trial failure of Durect's Posidur, which makes Exparel the 1st and only FDA approved extended release bupivacaine product on the market for a longer period of time.
Can someone help to explain why this is happening? Thanks.
Ski....I think the issue with PCRX is the skeptical view of how well they will do when they actually start selling product into the market. At this stage the "sales possibilities" look very encouraging but without true sales generation of Exparel currently, the stock price reflects a lot of speculation. Stocks like PCRX today are not rewarded based on projection or prediction that their very clever technology will produce revenue and earnings. They must go out now and earn their reward by converting sales in the market. Hopefully that will start happening sooner versus later. Stay patient. We won't hear about sales progress until June-July 2012.